Drug
Asciminib clinical trials
Also written ABL001.
- studies test it
- 29
- open now
- 13
- in phase 3
- 6
- first study started
- 2016
Keep track of what changes. Save the asciminib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- ABL001
- 24
Combined with it in one product
Studies by the year they started
29 studies that test it; most in 2021 (6)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 16
- Phase 3
- 6
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 13
Novartis Pharmaceuticals (16) · M.D. Anderson Cancer Center (4) · Thomas Ernst, PD Dr. med. (1) · University of Alabama at Birmingham (1) · City of Hope Medical Center (1) · Medical College of Wisconsin (1) · Duke University (1) · Korean Society of Hematology (1)
Often tested with
Tested in the same studies.
Dasatinib (3) · Imatinib (2) · Blinatumomab (2) · Nilotinib (2) · Trastuzumab (1) · Prednisone (1)
Studies
Open first, then newest update. How each study uses asciminib is read from its arms, and is right about nine times in ten.
Testing it · 29
- Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaRecruitingPhase 1City of Hope Medical CenterNCT07040982Written as Asciminib
- Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPRecruitingPhase 2Novartis PharmaceuticalsNCT07354074Written as Asciminib single agent
- Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.RecruitingPhase 2M.D. Anderson Cancer CenterNCT06236724Written as Asciminib
- Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06629584Written as Asciminib
- Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06308588Written as Asciminib
- Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid LeukemiaRecruitingPhase 1/2Novartis PharmaceuticalsNCT04925479Written as Asciminib Pediatric formulation group
- Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationRecruitingPhase 2Medical College of WisconsinNCT04838041Written as Asciminib 40 MG
- Asciminib in HER2+ Breast Cancer Brain MetastasesRecruitingPhase 1/2Duke UniversityNCT07136428Written as Asciminib and Trastuzumab
- Asciminib Roll-over StudyRecruitingPhase 4Novartis PharmaceuticalsNCT04877522Written as Asciminib single agent
- Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.RecruitingPhase 2Novartis PharmaceuticalsNCT06514534Written as ABL001/Asciminib
- A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid LeukemiaRecruitingPhase 2Korean Society of HematologyNCT06368414Written as Asciminib
- Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALLRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT07250087Written as Asciminib
- ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CMLRecruitingPhase 1Marlise Luskin, MDNCT03595917Written as ABL001
- A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPActive, not recruitingPhase 3Novartis PharmaceuticalsNCT04971226Written as Asciminib
- Efficacy of Asciminib in Chronic Phase CML Patients With T315I MutationsActive, not recruitingPhase 2Thomas Ernst, PD Dr. med.NCT07789574Written as asciminib 200 mg BID
- A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05456191Written as Asciminib
- Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIsCompletedPhase 3Novartis PharmaceuticalsNCT03106779Written as Asciminib
- Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic PhaseActive, not recruitingPhase 2University of Alabama at BirminghamNCT05143840Written as Single Agent Asciminib
- A Study of Full Treatment-free Remission in Patients With Chronic Myeloid LeukemiaTerminatedPhase 2Novartis PharmaceuticalsNCT03874858Written as Asciminib
- Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I MutationCompletedPhase 4Novartis PharmaceuticalsNCT06427811Written as Asciminib
See all 29 studies that test asciminib →
Given in every arm · 6 — asciminib is usual care beside what is tested
- Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)RecruitingPhase 1/2Novartis PharmaceuticalsNCT07387926Written as Asciminib Adult formulation
- Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AMLNot yet recruitingPhase 1/2M.D. Anderson Cancer CenterNCT07604233Written as Asciminib
- Asciminib With or Without Sildenafil for Brain TumorsNot yet recruitingEarly Phase 1Washington University School of MedicineNCT07039760Written as Asciminib
- PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLRecruitingPhase 2Gruppo Italiano Malattie EMatologiche dell'AdultoNCT06409936Written as Asciminib
- Frontline Asciminib Combination in Chronic Phase CMLActive, not recruitingPhase 2University of JenaNCT03906292Written as Asciminib
- A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALLCompletedPhase 1Novartis PharmaceuticalsNCT02081378Written as Asciminib (ABL001)
Codes
What other systems call asciminib · ClinicalTrials.gg INT000758
- MeSH (NLM) C000621806asciminibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) L1F3R18W77ASCIMINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2584304One source FDA
- Wikidata Q27074535asciminibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C114494AsciminibOne source FDA
- DrugBank DB12597One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000621806 | asciminib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | L1F3R18W77 | ASCIMINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2584304 | — | One source FDA |
| Wikidata | Q27074535 | asciminib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C114494 | Asciminib | One source FDA |
| DrugBank | DB12597 | — | One source Wikidata |
Also registered as asciminib hydrochloride (UNII C5U34S9XFV · RxNorm 2584303).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.